Our Small Molecule-Oligonucleotide Conjugation services help biotechnology companies, research teams, assay developers, and academic laboratories create chemically defined oligonucleotide conjugates for targeting, uptake, labeling, capture, and chemical biology studies. A small molecule can add a function that the nucleic acid sequence alone does not provide, but the final construct must still retain acceptable hybridization behavior, solubility, structural integrity, and compatibility with downstream experiments.
We integrate oligonucleotide design, reactive-handle planning, linker selection, conjugation chemistry, purification development, and analytical verification into one coordinated workflow. Projects can begin with a customer-defined DNA, RNA, siRNA, antisense oligonucleotide, aptamer, or probe sequence, or with a customer-supplied small molecule that requires feasibility review before attachment. Our broader oligonucleotide conjugation services can also support programs that combine several labels, ligands, or modification types.
Figure 1. Schematic diagram of a method for the synthesis of bifunctional small molecule-oligonucleotide hybrids. (Bhattarai, U; et al, 2020)
Conjugation Changes Oligonucleotide Function: A ligand positioned too close to a recognition region can reduce duplex formation, interfere with strand loading, or limit target accessibility. We assess terminal, internal, and strand-specific attachment options before chemistry selection so the small molecule is presented without unnecessarily compromising the oligonucleotide's intended function.
The Small Molecule and Oligonucleotide Behave Differently: Oligonucleotides are highly polar and charged, whereas many ligands, lipids, dyes, vitamins, and chemical probes are poorly soluble in aqueous media. This polarity mismatch can produce low conversion, precipitation, adsorption losses, or inconsistent reaction behavior. We select solvent systems, spacers, concentrations, and reaction order around the properties of both components.
Functional Groups May Not Be Compatible: A customer-supplied molecule may contain amines, acids, alcohols, thiols, heterocycles, or sensitive motifs that complicate selective coupling. We review available handles, protecting-group needs, synthesis tolerance, and potential side reactions before recommending amide formation, thiol-selective chemistry, click ligation, or on-support installation.
Hydrophobic Conjugates Are Difficult to Purify: Cholesterol, tocopherol, long-chain lipids, and aromatic labels can shift chromatographic behavior, broaden peaks, and increase aggregation risk. Purification is therefore planned at the design stage rather than treated as a final cleanup step, with method choice guided by charge, hydrophobicity, oligonucleotide length, and impurity profile.
Mass Confirmation Alone Is Not Enough: The expected mass does not show whether free ligand, unconjugated oligonucleotide, shortmers, catalyst residues, or closely related side products remain. We combine identity testing with fit-for-purpose purity assessment and, when relevant, label-specific or duplex-integrity checks to create a more decision-useful analytical package.
Early Designs May Need Comparative Screening: When attachment position, spacer length, or ligand orientation is uncertain, building one construct can create an expensive false start. We can prepare matched variant sets that compare a limited number of rational designs and help research teams select a practical architecture before expanding the program.
Our service packages are configured around the oligonucleotide modality, the small molecule's structure, the intended attachment site, and the downstream research workflow. We support direct attachment, modular post-synthetic coupling, and synthesis-integrated approaches for custom DNA and RNA constructs, duplex oligonucleotides, probes, aptamers, and other modified sequences.
Each project is reviewed as a complete molecular system. Sequence chemistry, linker polarity, ligand stability, reaction selectivity, purification feasibility, and analytical readout are considered together so that the proposed route is not only chemically possible, but also practical to execute and interpret.
The functional role of the small molecule determines the most important design questions. The matrix below helps research teams connect ligand class with attachment logic, linker requirements, purification risk, and intended use before committing to a synthesis route.
| Small Molecule Role | Representative Classes | Attachment Priorities | Main Technical Risks | Typical Research Uses |
| Receptor-Binding Ligand | GalNAc-type ligands, folate, vitamins, sugars, and other receptor-recognition motifs | Preserve ligand accessibility, control orientation, and avoid masking the oligonucleotide's active region | Steric shielding, insufficient spacer length, multivalency complexity, and difficult impurity separation | Receptor-mediated uptake studies, ligand screening, and cell-selective delivery research |
| Lipophilic Modifier | Cholesterol, tocopherol, fatty-acid derivatives, sterol-like molecules, and hydrophobic anchors | Balance membrane interaction with aqueous handling, duplex behavior, and storage stability | Aggregation, adsorption losses, broad chromatographic peaks, and reduced solubility | Membrane-association studies, uptake screening, and delivery-format comparison |
| Reporter Molecule | Fluorophores, chromophores, electroactive labels, and environment-sensitive dyes | Position the reporter away from quenching sites and preserve target recognition or signal response | Photophysical changes, dye hydrophobicity, incomplete free-dye removal, and signal background | Imaging probes, hybridization assays, sensor development, and localization studies |
| Affinity Tag | Biotin and other compact capture or enrichment handles | Maintain tag accessibility while limiting interference with hybridization and surface binding | Steric restriction, nonspecific interactions, free-tag carryover, and support-dependent performance | Pull-down assays, enrichment workflows, immobilization, and interaction studies |
| Bioorthogonal Handle | Azide, alkyne, strained alkyne, tetrazine, and compatible ligation partners | Select a handle pair that survives oligonucleotide synthesis and remains accessible during final ligation | Handle instability, steric congestion, copper exposure, and reagent-derived impurities | Modular conjugate assembly, multistep labeling, surface attachment, and screening libraries |
| Responsive Module | Photocages, redox-sensitive motifs, pH-responsive groups, and other triggerable small molecules | Match linker cleavage or activation behavior to the experimental environment and readout | Premature activation, incomplete release, side-product formation, and analytical complexity | Controlled activation studies, mechanistic experiments, and stimulus-responsive probe design |
Chemistry selection should reflect the functional groups available on both partners, the sensitivity of the small molecule, the oligonucleotide's modification pattern, and the ability to purify the final product. The guide below summarizes common route options and the factors that usually determine whether they are suitable.
| Conjugation Strategy | Compatible Handles | Best-Fit Situations | Critical Considerations | Typical Verification |
| Synthesis-Integrated Installation | Modifier phosphoramidites, terminal activatable groups, or support-bound modules | Compact molecules that tolerate oligonucleotide synthesis, cleavage, and deprotection | Reagent compatibility, coupling efficiency, steric effects, and stability during deprotection | Mass confirmation, chromatographic purity, and modifier-specific signal checks |
| NHS Ester-Amine Coupling | Activated ester on the small molecule and primary amine on the oligonucleotide | Fluorophores, biotin-type labels, and ligands available as activated esters | Activated-ester hydrolysis, competing amines, pH control, and small-molecule solubility | LC-MS where compatible, HPLC purity, and free-ligand assessment |
| EDC-Enabled Amide Coupling | Carboxyl-containing small molecule and amino-modified oligonucleotide | Custom molecules more readily prepared as carboxylic acids than activated esters | Activation efficiency, hydrolysis, side reactions, and removal of coupling reagents | Identity testing, chromatographic purity, and reaction-byproduct review |
| Maleimide-Thiol Coupling | Maleimide and free thiol | Chemoselective terminal attachment and modular linker installation | Thiol oxidation, maleimide hydrolysis, reaction timing, and linkage stability in the intended environment | Mass confirmation, HPLC or CE purity, and residual-thiol assessment when needed |
| CuAAC Click Ligation | Azide and terminal alkyne | Robust modular assembly when both partners tolerate copper-catalyzed conditions | Catalyst exposure, copper removal, oxidative side reactions, and ligand solubility | Identity testing, purity analysis, and residual-reagent review |
| SPAAC Click Ligation | Azide and strained cyclooctyne | Copper-free attachment of sensitive oligonucleotides or small molecules | Handle size, hydrophobicity, steric demand, reagent stability, and close-running impurities | LC-MS where compatible, chromatographic purity, and free-handle removal |
| IEDDA Ligation | Tetrazine and strained alkene partners | Rapid, orthogonal assembly for advanced modular constructs and sequential labeling | Handle stability, reagent availability, steric presentation, and side-product separation | Identity confirmation, HPLC or CE analysis, and label-specific checks |
The workflow is designed to identify chemistry and purification risks before valuable oligonucleotide or small-molecule material is committed. Each stage creates a clear decision point and a defined deliverable for the customer.
We collect the oligonucleotide sequence, modality, modification pattern, strand arrangement, desired scale, purity expectation, small-molecule structure, available functional groups, and intended research use. Existing customer material can be reviewed for suitability before a new synthesis is proposed.
Attachment site, handle chemistry, linker architecture, reaction order, solvent compatibility, and purification strategy are evaluated together. The customer receives a practical route recommendation, including key limitations and any proposed design variants.
The required amino, thiol, azide, alkyne, or other reactive handle is introduced during oligonucleotide synthesis or through a suitable post-synthetic step. Linker and small-molecule intermediates are prepared or conditioned for selective coupling.
Coupling is performed under conditions selected for conversion, selectivity, oligonucleotide integrity, and small-molecule stability. For higher-risk builds, reaction parameters or a small design set may be screened before the preferred route is finalized.
Free ligand, unconjugated oligonucleotide, short sequences, catalysts, salts, and close impurities are removed using a method matched to the conjugate's charge and hydrophobic profile. The final material is exchanged into a practical buffer or presentation format where appropriate.
Identity, purity, and agreed label- or structure-specific attributes are reviewed before release. The customer receives the purified conjugate, analytical records, material information, recommended handling conditions, and support for repeat builds or follow-on optimization.
Figure 2. Service flow of small molecule-oligonucleotide conjugation.
Small molecule-oligonucleotide conjugation requires coordinated expertise in nucleic acid chemistry and small-molecule reactivity. Our platform is structured to reduce avoidable redesign, protect scarce project materials, and provide conjugates that are easier to evaluate in downstream research.
Small molecules can give oligonucleotides new targeting, uptake, capture, optical, chemical, or responsive properties. We tailor conjugation design to the experimental question rather than using a single standard architecture across unrelated applications.
Share your oligonucleotide sequence or modality, small-molecule structure, available functional groups, preferred attachment site, target quantity, purity expectation, and intended research use. Our team can review route feasibility, recommend linker and handle options, identify likely purification challenges, and define an analytical package suited to the construct. Whether the project involves a targeting ligand, lipophilic modifier, affinity tag, reporter molecule, chemical probe, or custom research ligand, we provide coordinated support from design through purified conjugate delivery. Contact us to request a technical assessment or project quotation.
Small molecules are chemically linked to oligonucleotides to form conjugates with unique properties. This linkage enables the combination of the small molecule's functionality with the sequence specificity of oligonucleotides.
These conjugates are used in bioimaging, diagnostics, and controlled drug delivery. They also aid in gene expression regulation and detecting molecular interactions.
Small molecules like drugs, hormones, enzyme cofactors, dyes, toxins, and metabolites can all be conjugated with oligonucleotides. The choice depends on the desired application.
By attaching small molecules to oligonucleotides, it's possible to selectively regulate gene expression. This can be used for gene silencing or activating specific pathways in research.
Purification is carried out using advanced techniques like HPLC, MS, and PAGE. These methods ensure that the conjugates are of the highest purity and quality.
These conjugates can serve as probes or sensors, enabling the detection of specific nucleic acid sequences in biological samples. Their ability to bind to target molecules enhances diagnostic sensitivity.
Loading ......
